How should the fixed‑dose combination of zidebactam (1 g) and cefepime (2 g) be used to treat adult patients with confirmed or suspected carbapenem‑resistant Gram‑negative bacilli infections, including dosing, renal adjustment, treatment duration, and monitoring?

Zidebactam/Cefepime for CRGNB Infections: Clinical Implementation Guide

Zidebactam/cefepime (ZAYNICH) should be dosed at 3 grams (2g cefepime + 1g zidebactam) IV every 8 hours over 1 hour for 7-10 days in patients with eGFR ≥60 mL/min, with mandatory dose reductions for renal impairment. 1

FDA-Approved Indication and Current Role

Zidebactam/cefepime received FDA approval in May 2026 specifically for complicated urinary tract infections (cUTI) including pyelonephritis caused by susceptible Gram-negative organisms 1, 2. While not yet broadly indicated for all CRGNB infections, this agent represents a mechanistically unique option that combines β-lactamase inhibition with β-lactam enhancement through PBP2 binding 3, 4.

The current evidence base positions this agent as a potential carbapenem-sparing option for ESBL-producing Enterobacterales and shows promise against extensively drug-resistant (XDR) pathogens, including those resistant to other novel β-lactam/β-lactamase inhibitor combinations 5, 6, 4.

Dosing Algorithm

Standard Dosing (eGFR ≥60 mL/min)

• Dose: 3 grams (2g cefepime + 1g zidebactam) IV
• Frequency: Every 8 hours
• Infusion time: 1 hour
• Duration: 7-10 days 1

Renal Dose Adjustments (Mandatory)

eGFR 60-89 mL/min:

• 3 grams every 8 hours (no adjustment needed) 1

eGFR 30-59 mL/min:

• 1.5 grams (1g cefepime + 0.5g zidebactam) every 8 hours 1

eGFR 15-29 mL/min:

• 1.5 grams every 12 hours 1

eGFR 8-14 mL/min (with or without hemodialysis):

• 1.5 grams every 24 hours
• Critical timing for hemodialysis patients: Administer dose AFTER dialysis session on dialysis days; on non-dialysis days, give 24 hours after previous dose 1

Calculation Method

Use the 4-variable MDRD formula to calculate eGFR for dose determination 1.

Clinical Positioning Within CRGNB Treatment Guidelines

When to Consider Zidebactam/Cefepime

Primary scenarios based on current evidence:

1. ESBL-producing Enterobacterales (carbapenem-sparing strategy):

   • For cUTI/pyelonephritis with confirmed susceptibility
   • Consider when carbapenem stewardship is a priority 4

2. Ceftazidime/avibactam-resistant KPC-producing organisms:

   • Demonstrates potent activity against KPC variants (KPC-31, KPC-14, KPC-33, KPC-93, KPC-203, KPC-205, KPC-49, KPC-167) that confer ceftazidime/avibactam resistance 6
   • Notably, zidebactam activity is NOT influenced by different KPC variants 6

3. XDR Pseudomonas aeruginosa (including MBL-producers):

   • Case evidence supports use in NDM-producing, XDR P. aeruginosa when other options fail 5
   • May retain activity against cefiderocol- or aztreonam/avibactam-resistant strains 4

4. Salvage therapy for refractory infections:

   • Consider when polymyxin-based or other novel β-lactam/β-lactamase inhibitor combinations have failed 5

Integration with Existing CRGNB Guidelines

The 2023 guidelines for CRGNB management 7 and 2022 ESCMID guidelines 8 establish the following hierarchy that contextualizes where zidebactam/cefepime fits:

For CRE infections (guideline-recommended first-line agents):

• Ceftazidime/avibactam or meropenem/vaborbactam for severe infections (conditional recommendation, moderate/low evidence) 8
• Cefiderocol for MBL-producing CRE or pan-resistant organisms (conditional recommendation, low evidence) 8

Zidebactam/cefepime positioning:

• Use when ceftazidime/avibactam resistance emerges (particularly KPC variants) 6
• Consider for carbapenem-sparing in susceptible ESBL-producers 4
• Reserve for XDR organisms unresponsive to guideline-recommended agents 5

For CRAB infections:

• Guidelines recommend polymyxin combination therapy (strong recommendation, moderate evidence) 7
• Tigecycline-based and polymyxin-based combinations are equally preferable (weak recommendation, very low evidence) 7
• Zidebactam/cefepime data for CRAB remain limited; defer to established guideline recommendations

Monitoring Requirements

Renal Function Monitoring

Critical for cefepime component neurotoxicity risk:

• Monitor serum creatinine and calculate eGFR at baseline
• Reassess renal function every 48-72 hours during therapy
• Immediate dose adjustment required if eGFR drops below 60 mL/min 1
• Cefepime neurotoxicity occurs primarily in patients with renal impairment receiving inadequate dose adjustments 1

Neurotoxicity Surveillance

Watch for:

• Altered mental status
• Confusion, disorientation
• Myoclonus, seizures
• Encephalopathy

Action: Discontinue immediately if neurotoxicity occurs and provide supportive care 1

Hypersensitivity Monitoring

• Assess for β-lactam allergy history before initiation (contraindication if serious prior reaction) 1
• Monitor for signs of anaphylaxis, particularly with first dose
• Discontinue and provide supportive measures if allergic reaction occurs 1

Clostridioides difficile Surveillance

• Evaluate any diarrhea that develops during or after treatment 1
• Consider C. difficile testing if diarrhea is significant or persistent

Microbiological Monitoring

• Obtain cultures before initiating therapy whenever possible
• Perform susceptibility testing to confirm activity
• Consider repeat cultures if clinical response is inadequate after 48-72 hours

Treatment Duration

Standard duration: 7-10 days 1

Duration considerations:

• Base on infection severity, source control adequacy, and clinical response
• For cUTI/pyelonephritis: typically 7 days if uncomplicated, up to 10 days for severe cases
• For off-label use in severe CRGNB infections: extend to 10-14 days based on clinical judgment and source control
• Compassionate use case in refractory empyema used 21 days with successful outcome 5

Preparation and Administration

Reconstitution Protocol 1

1. Reconstitute vial: Add 10 mL of 0.9% NaCl, 5% dextrose, Lactated Ringer's, or sterile water
2. Mix gently to dissolve (concentration: ~240 mg/mL, final volume ~13 mL)
3. Stability after reconstitution:
   • Room temperature (20-25°C): up to 6 hours
   • Refrigerated (2-8°C): up to 12 hours
   • Protect from light (keep in outer carton)
4. Further dilute reconstituted solution into 100 mL infusion bag (use same diluent as reconstitution)
5. Administer over 1 hour via IV infusion

Critical: Reconstituted solution is NOT for direct injection and must be diluted 1

Common Pitfalls and How to Avoid Them

Pitfall 1: Inadequate Renal Dose Adjustment

Problem: Cefepime accumulation causes neurotoxicity in renal impairment Solution: Calculate eGFR using MDRD formula at baseline and every 48-72 hours; adjust dose immediately when eGFR drops below 60 mL/min 1

Pitfall 2: Using Beyond Approved Indication Without Susceptibility Data

Problem: FDA approval limited to cUTI; off-label use requires documented susceptibility Solution: Obtain cultures and susceptibility testing before using for non-approved indications; reserve for documented susceptible organisms or salvage situations 1, 2

Pitfall 3: Incorrect Hemodialysis Timing

Problem: Dialysis removes drug, leading to subtherapeutic levels Solution: Always administer dose AFTER hemodialysis session on dialysis days 1

Pitfall 4: Overlooking β-Lactam Allergy History

Problem: Serious hypersensitivity reactions including anaphylaxis Solution: Thoroughly assess β-lactam allergy history; absolute contraindication if serious prior reaction 1

Pitfall 5: Assuming Activity Against All CRGNB

Problem: Activity spectrum varies; not universally active against all resistance mechanisms Solution: Recognize optimal activity against ESBL-producers, KPC variants, and select XDR organisms; limited data for CRAB and other mechanisms 3, 6, 4

Resistance Considerations

Mechanisms that may affect activity:

• Porin loss (OmpK35/OmpK36 mutations)
• Efflux pump overexpression
• PBP alterations (though PBP2 binding by zidebactam may overcome some mutations)
• Evolving β-lactamase variants 3, 4

Surveillance strategy:

• Perform susceptibility testing when available
• Monitor for clinical failure suggesting resistance emergence
• Consider combination therapy for high-risk, severe infections (though data limited)

Future Directions and Evidence Gaps

Current limitations:

• Clinical data primarily from cUTI trials 2
• Limited evidence for bloodstream infections, pneumonia, and other severe infections
• No established clinical breakpoints for many organisms
• Combination therapy data lacking

Ongoing development:

• Phase 3 trials for broader indications
• Evaluation in severe infections beyond cUTI
• Resistance surveillance studies
• Combination strategies for complex resistance 3, 4

Clinical decision-making in evidence gaps: Given limited clinical data beyond cUTI, use zidebactam/cefepime for non-approved indications only when: (1) susceptibility is documented, (2) other guideline-recommended options have failed or are unavailable, and (3) infection severity justifies off-label use with appropriate informed consent and institutional approval 5.